Plasma levels of Interleukin 18 but not amyloid-β or Tau are elevated in female depressive patients

Plasma levels of Interleukin 18 but not amyloid-β or Tau are elevated in female depressive patients

Background: Depression is associated with inflammation and Alzheimer's disease (AD). However, detailed molecular mechanisms linking mood, neuroinflammation and AD remain unclear. Although changes in peripheral inflammatory factors such as Interleukin 18 (IL18), and AD-associated amyloid-β (Aβ)...

Full description

Bibliographic Details
Main Authors:	Fa-rong Liu, Lu-yin Yang, Hui-fei Zheng, Yunqiang Zhou, Bin-bin Chen, Huaxi Xu, Yun-wu Zhang, Dong-yan Shen
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	Comprehensive Psychiatry
Online Access:	http://www.sciencedirect.com/science/article/pii/S0010440X20300018

Similar Items

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
by: Yuan Cheng, et al.
Published: (2022-05-01)

Relation of plasma β‐amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study
by: José Rafael Romero, et al.
Published: (2020-07-01)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
by: Shannon L. Risacher, et al.
Published: (2019-12-01)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
by: Lauren E. McCollum, et al.
Published: (2021-01-01)

Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer’s disease
by: Zhi-Bo Wang, et al.
Published: (2022-12-01)

Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China
by: Bin Jiao, et al.
Published: (2021-10-01)

Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation
by: Nalini V. Gorantla, et al.
Published: (2021-04-01)

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
by: Westwood, S, et al.
Published: (2018)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
by: Sarah Westwood, et al.
Published: (2018-12-01)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
by: Jingshan Chen, et al.
Published: (2023-05-01)

Soluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo
by: Tomas Ondrejcak, et al.
Published: (2019-07-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
by: Daniel J. Figdore, et al.
Published: (2024-01-01)

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study
by: Tosca O. E. deCrom, et al.
Published: (2024-01-01)

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals
by: Qingling Sun, et al.
Published: (2022-08-01)

Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife
by: Minos Kritikos, et al.
Published: (2020-04-01)

Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation
by: Woo Shik Shin, et al.
Published: (2019-10-01)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
by: Yara Mashal, et al.
Published: (2022-07-01)

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection
by: Sarah K. Yeo, et al.
Published: (2020-07-01)

Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology
by: Annerieke Sierksma, et al.
Published: (2018-10-01)

Elevating the Levels of Calcium Ions Exacerbate Alzheimer’s Disease via Inducing the Production and Aggregation of β-Amyloid Protein and Phosphorylated Tau
by: Pei-Pei Guan, et al.
Published: (2021-05-01)

Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [18F]UCB-H PET imaging
by: Letizia Vogler, et al.
Published: (2023-01-01)

Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson’s disease: a follow-up study
by: Lung Chan, et al.
Published: (2023-01-01)

Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
by: Yue Cai, et al.
Published: (2023-02-01)

Correction to: Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation
by: Woo Shik Shin, et al.
Published: (2021-04-01)

Assessment of tau phosphorylation and β‐amyloid pathology in human drug‐resistant epilepsy
by: Alisha Aroor, et al.
Published: (2023-06-01)

Neurotrophin receptor p75 mediates amyloid β-induced tau pathology
by: Lin-Lin Shen, et al.
Published: (2019-12-01)

TDP-43 expression influences amyloidβ plaque deposition and tau aggregation
by: Stephani A. Davis, et al.
Published: (2017-07-01)

Mesial temporal tau in amyloid-β-negative cognitively normal older persons
by: Natasha Krishnadas, et al.
Published: (2022-04-01)

Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells
by: Sutinen Elina M, et al.
Published: (2012-08-01)

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
by: Fernando Gonzalez-Ortiz, et al.
Published: (2024-04-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
by: Carla M. Startin, et al.
Published: (2019-03-01)

Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1β in macrophages.
by: Kyoko Hara, et al.
Published: (2014-01-01)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
by: Samar Rahhal, et al.
Published: (2023-12-01)

Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
by: Nunzio Pomara, et al.
Published: (2022-07-01)

Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice
by: Alejandro R. Roda, et al.
Published: (2020-09-01)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
by: Karolina Wilczyńska, et al.
Published: (2020-10-01)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
by: Ross W. Paterson, et al.
Published: (2015-09-01)

A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity
by: Travis Rush, et al.
Published: (2020-02-01)

Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies
by: Elijah Mak, et al.
Published: (2024-04-01)